Anew Labs
An AI drug-discovery company that combines molecular models, experimental biology and a drug pipeline to identify and develop new medicines.
$290MFunding
LeadGV
GL Ventures
Activity from announced rounds
Activity in this selectionOct 24, 2026 · AI · Jan 1, 2026
GL Ventures is the Hillhouse-origin early-stage venture firm identified in LTZ and Clipto issuer announcements.
Recorded funding activity
LTZ develops cancer immunotherapies targeting myeloid biology. Clipto supplies tools for searching video and audio libraries, while Anew combines AI models and experiments for drug discovery. These histories remain distinct from the Hillhouse parent and named funds.
- Rounds participated in
- 10
- Confirmed lead rounds
- 1 4 roles undisclosed
- New companies
- 10 First participation on record · 0 follow-on
- Funding in participating rounds
- $623M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
10 in this selectionClipto
Clipto builds AI tools for searching and working with video and audio libraries.
$15MFunding
Participant子午线光年
子午线光年 is a Beijing company developing world-model AI technology.
UndisclosedAngel
ParticipantLatentVerse
LatentVerse develops foundation models that combine perception, prediction and robot action.
UndisclosedSeed
ParticipantMoSense
MoSense builds flexible tactile skin and sensing systems for robots.
UndisclosedAngel
ParticipantLitchibot
Litchibot develops physical-AI infrastructure that lets robot skills transfer across hardware.
UndisclosedSeed
ParticipantLTZ Therapeutics
LTZ Therapeutics develops cancer immunotherapies that target myeloid biology.
$38MUndisclosed
Role not disclosedSyneron Bio
Develops intelligent platform-driven macrocyclic peptide drug discovery
$150MSeries B
Role not disclosedDify
Helps teams build deploy and operate production-grade AI applications and agentic workflows
$30MPre-Series A
Role not disclosedEPG
Provides modular and prefabricated data center infrastructure
$100MSeries B
Role not disclosed